References
- Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ 2010;11(4):427-34
- Crott R, Versteegh M, Carin Uyl-de-Groot. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Qual Life Res 2013;22(5):1045-54
- Jang R, Isogai P, Mittmann N, et al. Derivation of utility values from European organization for research and treatment of cancer quality of life-core 30 questionnaire values in lung cancer. J Thorac Oncol 2010;5(12):1953-7
- McKenzie L, Van der Pol M. Mapping the EORTC QLQC-30 onto the EQ-5D instrument: the potential to estimate QALY’s without generic preference fata. Value Health 2009;12(1):167-71
- Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5 D, SF-6 D, and 15 D instruments. Value Health 2009;8:1151-7
- Versteegh MM, Leunis A, Luime JJ, et al. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decis Making 2012;32(4):554-68
- Kim E, Ko S, Kang YH. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BRC23 to the generic EQ-5D in metastatic breast cancer patients. Qual Life Res 2012;21:1193-203
- Kim SH, Jo MW, Kim HJ, Ahn JH. Mapping EORTC QLQC30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes 2012;10:151-5
- Wu E, Mulani P, Farrell M, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health 2007;10(5):408-14
- Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III Trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose- intensified epirubicin and cyclophosphamide _ filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21(5)):843-50
- Bottomley A, Therasse P, Piccart M, et al. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol 2005;6:287-94
- Efficace F, Therasse P, Piccart M, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic Breast Cancer Population: an international multicenter study. J Clin Oncol 2004;22(16):3381-8
- EORTC QLQC30 Scoring Manual. EORTC, Brussels, Belgium. Available from: http://groups.eortc.be/qol/documentation_manuals.htm
- Dolan P. Modeling Valuations for EuroQol Health States. Med Care 1997;35(11):1095-108
- McTaggart-Cowan H, Teckle P, Peacock S. Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature. Expert Rev Pharmacoecon Outcomes Res 2013;13(6):753-65
- Greene WH. Econometric analysis. 7th edition. Prentice Hall; New Jersey, USA: 2012
- Huang IC, Frangakis C, Atkinson MJ, et al. addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res 2008;43(1 Pt 1):327-39
- Hernandez-Alava M, Wailoo JH, Ara R. Tails from the peak district: adjusted censored mixture Models of EQ-5D health state utility values. Value Health 2012;15(3):550-61
- Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six country study. Eur J Health Econ 2003;4(3):222-31
- Karlsson JA, Nilsson JÅ, Neovius M, et al. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, USA and Danish utilities in south Swedish rheumatoid arthritis patients. Ann Rheum Dis 2011;70(12):2163-6
- Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010;11(2):215-25
- Rowen D, Brazier J, Young T, et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health 2011;14(5):721-31
- Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based measures: benefit or burden? Value Health 2012;15(3):504-13